Article Text

Download PDFPDF
An Increasing Role for Trabectedin in Gynecological Cancers: Efficacy in Uterine Sarcomas
  1. Isabelle Ray-Coquard, PhD, MD
  1. Centre Léon Bérard, Lyon, France.
  1. Address correspondence and reprint requests to Isabelle Ray-Coquard, PhD, MD, Centre Léon Bérard, Lyon, France. E-mail: ray{at}


Trabectedin is indicated for patients with advanced soft tissue sarcoma after failure of treatment with anthracyclines and ifosfamide or for patients who are unsuited to receive these agents. The agent has shown activity in patients with advanced uterine leiomyosarcoma, with an acceptable safety profile. Thus, the results of phase II studies have shown that treatment with trabectedin results in 30% progression-free survival at 6 months. More than 50% of these pretreated patients were alive at 1 year. The response rate, progression-free survival, and overall survival compared favorably with other single agents (eg, doxorubicin, ifosfamide, and gemcitabine), with clinical benefit in 50% of patients in second-line treatment. These results are being confirmed in a current prospective phase II study in first-line uterine leiomyosarcoma combining trabectedin with doxorubicin.

  • Trabectedin

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Disclosure: Editorial assistance for the preparation of this manuscript was funded by PharmarMar.